InsiderFinancial

$BTAI Triple Top At $12

Long
NASDAQ:BTAI   BioXcel Therapeutics, Inc
$BTAI should see a major breakout above $12. The risk/reward setup looks promising.

About BioXcel Therapeutics, Inc. :

BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology. BTI's drug re-innovation approach leverages existing approved drugs and/or clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI's two most advanced clinical development programs are BXCL501, an investigational sublingual thin film formulation in development for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an investigational orally administered systemic innate immunity activator in development for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com.

As always, use protective stops and trade with caution.

Good luck to all!
To receive our alerts via email and SMS, join Insider Financial for Free at https://signup.insiderfinancial.com

We are not financial advisors. Always conduct your own research and read our full disclaimer at https://insiderfinancial.com/disclaimer/